{"nctId":"NCT02692391","briefTitle":"A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis","startDateStruct":{"date":"2013-07","type":"ACTUAL"},"conditions":["Acute Pancreatitis"],"count":42,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Indomethacin suppository","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Indomethacin"]}],"interventions":[{"name":"Indomethacin","otherNames":["Indocin"]},{"name":"Placebo","otherNames":["Glycerin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* All patients ages 18 or above admitted to UPMC with a diagnosis of AP based on at least 2 of the following criteria:\n\n  (i) abdominal pain characteristic of AP (ii) serum amylase and/or lipase ≥ 3 times the upper limit of normal (iii) characteristic findings of AP on abdominal CT scan will be screened for study enrollment.\n* Patients with SIRS (≥ 2 of the following criteria: temperature \\<36°C or \\>38°C, heart rate \\>90/min, respiratory rate \\>20/min OR PaCO2\\<32 mmHg, WBC \\<4,000/mm3, \\>12,000/mm3 or \\>10% bands) upon hospital admission or who develop SIRS during their first week of hospitalization\n\nExclusion Criteria:\n\n* Presence of OF (shock defined by SBP\\<90mmHg, PO2\\<60mmHg on room air or need for mechanical ventilation, Cr≥2mg/dL)\n* Presence of renal dysfunction (Cr\\>1.5mg/dL)\n* Active peptic ulcer disease\n* Pregnancy\n* Use of daily NSAIDs within 1 week of presentation\n* Allergy to NSAIDs.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Systemic Inflammatory Response Syndrome (SIRS) Score","description":"SIRS is a simple clinical score, ranging from 0-4, that utilizes objective, routine clinical parameters (body temperature, heart rate, respiratory rate or arterial carbon dioxide tension and white blood count) that directly reflect the underlying inflammatory response. A lower change in SIRS score (negative number) indicates a better outcome (less inflammation).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.96","spread":"0.81"},{"groupId":"OG001","value":"-1","spread":"1.24"}]}]}]},{"type":"PRIMARY","title":"C-Reactive Protein (CRP) Levels.","description":"CRP levels at 48 hours after enrollment minus CRP levels at enrollment (baseline). A negative number indicates a better outcome (less inflammation).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.43","spread":"8.73"},{"groupId":"OG001","value":"-2.08","spread":"12.55"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Development of Organ Failure","description":"Including respiratory, renal and cardiovascular failures defined as modified Marshal score of equal and greater than 2. The minimum and maximum values in the modified Marshal score for each organ failure range from 0 to 4 with a higher value representing worse outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Mortality","description":"Enrolled subjects that died. A death indicates a worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":24},"commonTop":["Acute Kidney Injury","GI Bleed"]}}}